A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics
Completed
- Conditions
- Cancer
- Registration Number
- NCT01775514
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This non-interventional study will assess the occurrence rate of non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey, and the diagnostic methods and treatments used. Data will be collected over 36 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32277
Inclusion Criteria
- Participants diagnosed with non-small cell lung, colon, breast, gastric cancer and melanoma
- Participants who give consent to the collection of their information after the first record and pathological confirmation of their cancer
Exclusion Criteria
- Participants not living in the city or representative region of the study center
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region 36 months Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region 36 months Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region 36 months Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region 36 months Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region 36 months
- Secondary Outcome Measures
Name Time Method Percentage of Participants Categorized by Surgery Type 36 months Percentage of Participants Categorized by Diagnostic Methods 36 months Overall Survival (OS) 36 months Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 36 months Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments) 36 months Percentage of Participants With Metastasis Categorized by Treatment Regimens Used (ie, First-line, Second-line, Third-line, or Forth-line Chemotherapy) 36 months Percentage of Participants With History of Another Primary Cancer 36 months Percentage of Participants With Metastasis 36 months Percentage of Participants Categorized by Tumor Size 36 months Percentage of Participants Categorized by Histopathology Diagnosis 36 months Percentage of Participants Categorized by the Staging System 36 months Percentage of Participants With Family History of Cancer and Other Conditions 36 months Percentage of Participants Categorized by Tumor Localization 36 months